After Decades of Delays, RSV Vaccines Show Promise in Early Data
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
After Decades of Delays, RSV Vaccines Show Promise in Early Data
After Decades of Delays, RSV Vaccines Show Promise in Early Data
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The group’s 7-2 ruling in favor of the therapeutic represents a shift from previous deliberations, in which data on its effectiveness was deemed insufficient.
In this webinar, Andrew Hamilton and Joe Hirano will explore how to detect and remove host cell proteins and other impurities during biologics manufacturing.
The Scientist spoke to Mount Desert Island Biological Laboratory’s Jim Strickland about the institute’s new MDI Bioscience initiative to perform more drug testing and development in nonmammalian models.
The steroid’s exceptional performance in early results from the RECOVERY clinical trial in the United Kingdom is a rational outcome of the drug’s anti-inflammatory effects, experts say.
Martin Domnowski explains how sequence and formulation affect antibody self-interaction properties, and how researchers detect these interactions in low concentration samples.